Gulf Medical University College of Medicine and ScholarRx Announce Medical Education Partnership

LOUISVILLE, Ky., Dec. 2, 2020 /PRNewswire/ — Today the Gulf Medical University College of Medicine (GMU) and ScholarRx announced a collaboration to further the College’s educational mission. GMU has adopted the Rx Bricks online service from ScholarRx, a revolutionary digital learning platform that supports the curriculum and enhances pre-clinical instruction.

ScholarRx (PRNewsfoto/ScholarRx)

Prof. Hossam Hamdy, Chancellor, Gulf Medical University states, “Gulf Medical University’s partnership with ScholarRx ensures that the content of the medical curriculum is benchmarked with similar top U.S. medical colleges using the same program. The Rx Bricks of ScholarRx provide our students with up-to-date medical knowledge through educationally sound courses delivered by expert faculty. As a leading medical university in the Middle East, Gulf Medical University will contribute to the continuous development of ScholarRx by integrating its Virtual Patient Learning (VPL) technology in the Rx Bricks, conducting research, and evaluating the educational impact of ScholarRx.  I am sure our students and faculty will appreciate the value of ScholarRx.” 

GMU uses the innovative Rx Bricks digital learning platform from ScholarRx to better engage and align medical students with the curriculum. This has become especially important as more learning is taking place online. With this new set of resources, faculty teaching GMU students can:

  • Assign specific Rx Bricks through their learning management system
  • Use question banks accompanying the Rx Bricks for both formative and summative assessments, and
  • Provide foundational support to their virtual patient learning sessions.

“Collaboration with ScholarRx has enriched and added value to our existing online learning resources, as the College of Medicine has been able to seamlessly integrate the Rx Bricks in the medical curriculum. Faculty and students alike have embraced it with ease due to the user-friendly nature of the resource,” said Prof. Manda Venkatramana, Vice-Chancellor Academics and Dean, College of Medicine at Gulf Medical University.

“GMU has developed into a leading institution for medical education in the Middle East under the visionary leadership of Chancellor Hamdy and Vice-Chancellor Manda,” said Dr. Tao Le, Founder and CEO of ScholarRx. “We are pleased to support their remarkable work in digital curricular innovation.”

About Gulf Medical University College of Medicine
The vision of the university is to be a leading international academic healthcare institution through the integration of quality health professions education, research, healthcare, and social accountability for sustainable community development. The College of Medicine, in existence since 1998, has managed to not only impart quality medical education, but has also created a network of healthcare services, a conducive research milieu, and developed unique related avenues for professional development, policy, and leadership to meet the healthcare needs of the nation and the region.

About ScholarRx
ScholarRx is a mission-driven education organization currently serving over 150,000 medical students and physician learners annually.  ScholarRx has developed a revolutionary componentized, multi-competency curricular platform that empowers medical schools and their faculty to rapidly develop high-quality education experiences, even in resource-poor environments.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gulf-medical-university-college-of-medicine-and-scholarrx-announce-medical-education-partnership-301183960.html

SOURCE ScholarRx

Source Article

Read more

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

(MENAFN – Newsfile Corp) Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia–(Newsfile Corp. – November 30, 2020) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (” Lobe ” or the ” Company “) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (” NAC “) for the treatment of mild traumatic brain injury/concussion (” mTBI “) with post-traumatic stress disorder (” PTSD “). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

The Miller School of Medicine is an internationally recognized leader in medical research, ranked No. 39 among the top medical schools in the nation by Blue Ridge Institute for Medical Research. In 2019, the medical school submitted 1,968 research proposals and was awarded $149 million in research funding from the National Institutes of Health (NIH).

Advances in neuro-diagnostic assessment have revealed mild traumatic brain injury (concussion) is more common than previously thought and potentially associated with a host of negative health outcomes. The Centers for Disease Control (” CDC “) estimates that there are 3 million emergency room visits and over 230,000 hospitalizations due to TBI in any given year in the United States alone. Also, at the same time there are 5.3 million Americans living with the effects of mTBI (a 53% increase over ten years ago). The World Health Organization calls traumatic brain injury a “silent epidemic” that affects over 70 million individuals across the world. The United States Department of Defense estimates that over 345,000 individuals are affected by mTBI and that 20% of all service members who deploy suffer mTBI. mTBI and PTSD are significant health care issues that often co-occur and impact each other.

Dr. Hoffer, the principal investigator on the study, said, “This a very important extension of our work with NAC and other medicines to identify new treatments for mTBI and PTSD. We are hopeful that this new combination of psilocybin with NAC will lead us to better solutions for those suffering from mTBI and/or PTSD.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are very excited to begin the preclinical studies in collaboration with Dr.

Read more

Ross University School of Veterinary Medicine Partners With MANRRS to Increase Diversity in Veterinary Profession

Pet owners represent a much more diverse population than the veterinary professionals who care for them and their animals, a gap the American Veterinary Medicine Association (AVMA)1 and the Association of American Veterinary Colleges (AAVMC) 2 are working hard to fill. Ross University School of Veterinary Medicine (RUSVM) is committed to being part of the solution and is proud to announce a new partnership with Minorities in Agriculture, Natural Resources and Related Sciences (MANRRS). This collaboration will further RUSVM’s long-term commitment to increase diversity in the veterinary profession and strengthen the pipeline of highly qualified, diverse students pursuing an education in veterinary medicine.

The partnership will introduce RUSVM to MANRRS chapters across the U.S. with MANRRS members gaining access to exclusive webinars and virtual workshops from RUSVM to increase exposure to the profession. Additionally, qualified students may apply for a newly launched MANRRS scholarship. The partnership will also help establish a professional chapter of MANRRS at RUSVM that will create mentoring opportunities for current RUSVM students and enhanced networking opportunities. To learn more about this partnership, click here.

“It is vitally important that the field of veterinary medicine is representative of the communities that we serve, and Ross University School of Veterinary Medicine is thrilled to take this important step toward increasing diversity in the field,” said Sean Callanan, MVB, CERTVR, MRCVS, PHD, FRCPATH, DIPLECVP, dean of Ross University School of Veterinary Medicine. “As one of the most ethnically diverse AVMA-accredited veterinary schools, the partnership with MANRRS will provide new opportunities for prospective, current and former students, and pave the way for a more diverse workforce.”

According to an American Veterinary Medicine Association (AVMA) report, more than one-third of African Americans surveyed own a pet. However, the vast majority of practicing veterinarians in the U.S. are white3, highlighting a disparity in the diversity of the profession and the people that they serve.

“While facing the dismal reality that more than 85% of Veterinarians are white, MANRRS is committed to partnering with RUSVM to provide underrepresented students access to pursue a career in veterinary medicine,” said Ebony Webber, chief operating officer for MANRRS. “Provided that MANRRS is one of the only and largest organizations focused on diverse talent in agriculture, our student and professional members expect MANRRS to advocate for diversity, equity, and inclusion in areas where minorities are needed to help solve the world’s biggest challenges relating to animal health.”

RUSVM, supported by its parent company, Adtalem Global Education, is committed to cultivating a culture of diversity and inclusivity and creating a diverse global workforce that reflects that culture. To learn more about Adtalem’s commitment to diversity and inclusion, click here.

About Ross University School of Veterinary Medicine

Ross University School of Veterinary Medicine (RUSVM) is an institution of Adtalem Global Education (NYSE:ATGE, member S&amp, P MidCap 400 Index)). Founded in 1982, RUSVM is committed to preparing students to become members and leaders of the worldwide public and professional healthcare team and to advance human, animal and

Read more

Ross University School of Veterinary Medicine Partners With MANRRS to Increase Diversity in Veterinary Profession – Press Release

BASSETERRE, St. Kitts–(Business Wire)–Pet owners represent a much more diverse population than the veterinary professionals who care for them and their animals, a gap the American Veterinary Medicine Association (AVMA)1 and the Association of American Veterinary Colleges (AAVMC) 2 are working hard to fill. Ross University School of Veterinary Medicine (RUSVM) is committed to being part of the solution and is proud to announce a new partnership with Minorities in Agriculture, Natural Resources and Related Sciences (MANRRS). This collaboration will further RUSVM’s long-term commitment to increase diversity in the veterinary profession and strengthen the pipeline of highly qualified, diverse students pursuing an education in veterinary medicine.

The partnership will introduce RUSVM to MANRRS chapters across the U.S. with MANRRS members gaining access to exclusive webinars and virtual workshops from RUSVM to increase exposure to the profession. Additionally, qualified students may apply for a newly launched MANRRS scholarship. The partnership will also help establish a professional chapter of MANRRS at RUSVM that will create mentoring opportunities for current RUSVM students and enhanced networking opportunities. To learn more about this partnership, click here.

“It is vitally important that the field of veterinary medicine is representative of the communities that we serve, and Ross University School of Veterinary Medicine is thrilled to take this important step toward increasing diversity in the field,” said Sean Callanan, MVB, CERTVR, MRCVS, PHD, FRCPATH, DIPLECVP, dean of Ross University School of Veterinary Medicine. “As one of the most ethnically diverse AVMA-accredited veterinary schools, the partnership with MANRRS will provide new opportunities for prospective, current and former students, and pave the way for a more diverse workforce.”

According to an American Veterinary Medicine Association (AVMA) report, more than one-third of African Americans surveyed own a pet. However, the vast majority of practicing veterinarians in the U.S. are white3, highlighting a disparity in the diversity of the profession and the people that they serve.

“While facing the dismal reality that more than 85% of Veterinarians are white, MANRRS is committed to partnering with RUSVM to provide underrepresented students access to pursue a career in veterinary medicine,” said Ebony Webber, chief operating officer for MANRRS. “Provided that MANRRS is one of the only and largest organizations focused on diverse talent in agriculture, our student and professional members expect MANRRS to advocate for diversity, equity, and inclusion in areas where minorities are needed to help solve the world’s biggest challenges relating to animal health.”

RUSVM, supported by its parent company, Adtalem Global Education, is committed to cultivating a culture of diversity and inclusivity and creating a diverse global workforce that reflects that culture. To learn more about Adtalem’s commitment to diversity and inclusion, click here.

About Ross University School of Veterinary Medicine

Ross University School of Veterinary Medicine (RUSVM) is an institution of Adtalem Global Education (NYSE: ATGE; member S&P MidCap 400 Index). Founded in 1982, RUSVM is committed to preparing students to become members and leaders of the worldwide public and professional healthcare team and to advance

Read more

Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

BETHESDA, Md. and BALTIMORE, Nov. 30, 2020 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM), to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD). STARs are proprietary small molecules targeting novel allosteric binding sites on enzymes. These small molecule drug candidates are designed to cross the blood brain barrier and penetrate other hard to treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Research will be led by Ricardo A. Feldman, Ph.D., Associate Professor, of Microbiology and Immunology in UMSOM.

Under the terms of the collaboration, UMSOM will investigate Gain’s STAR candidates in macrophage and neuronal models of nGD and GBA-associated PD. These diseases are characterized by mutations in the GBA gene, where misfolding of the enzyme encoded by GBA (beta-glucocerebrosidase (GCase)) interferes with its normal transport to the lysosome. The research program will aim to further elucidate the mechanism of action of Gain’s STAR candidates by studying their effect on GCase, including GCase’s enzyme activity and transport to the lysosome. Additionally, other effects such as prevention of alpha-synuclein aggregation in PD dopaminergic neurons will be evaluated.

“We are exceedingly proud to be advancing our work in nGD and Parkinson’s in close collaboration with the University of Maryland School of Medicine,” said Eric Richman, Chief Executive Officer at Gain. “The expertise and experience of UMSOM and Dr. Feldman will be instrumental as we work to further validate the exciting potential of Gain’s STAR candidate for these devastating diseases. I am confident these foundational studies will bring us closer to a potential new treatment option for those with these disorders.”

Dr. Feldman added, “Our laboratory has used human induced pluripotent stem cell (iPSC) models of GD and GBA-associated PD to uncover the molecular mechanisms leading to these diseases. We have also developed very sensitive assays to evaluate the therapeutic efficacy of small molecules in reversing the phenotypic abnormalities caused by mutant GBA in the cell types affected by these diseases, including macrophages and neuronal cells. I have been impressed by Gain’s initial results evaluating the potential of STARs in correcting enzyme misfolding and restoring function, and look forward to working with Gain’s team to further advance its program to treat these diseases.”

Gain and UMSOM intend to report initial data from the collaboration in the first half of 2021.

About Gain Therapeutics, Inc.
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for

Read more

Stanford faculty demand university sanctions for Trump adviser and faculty member Scott Atlas

Scott Atlas; Donald Trump
Scott Atlas; Donald Trump

US President Donald Trump (L) listens to White House coronavirus adviser Dr. Scott Atlas speak during a press conference in the Brady Briefing Room of the White House on September 23, 2020, in Washington, DC. MANDEL NGAN/AFP via Getty Images

This article originally appeared here on Salon.com

Scott Atlas, one of President Trump’s special coronavirus advisers and a faculty member at Stanford University’s Hoover Institution in Palo Alto, Calif., is causing a minor fracas among students and faculty at the elite university. Specifically, Atlas’ recommendations on coronavirus public health measures fly in the face of scientific consensus, faculty says — a charge that Atlas denies, and which he has threatened litigation over.  

During a Faculty Senate meeting at Stanford University late last month, the college’s president and provost were asked whether Dr. Scott Atlas should face university sanctions for positions he has taken about the novel coronavirus pandemic that go against the scientific consensus. (As the faculty noted, Atlas is a neuroradiologist, not an epidemiologist or a scholar of infectious disease.) At the meeting, similar questions were raised about the university’s relationship with the Hoover Institution, where Atlas is a senior fellow. The Hoover Institution is a conservative think tank located on Stanford’s campus that has supported a laundry list of prominent right-wing statesmen over the years, from Condoleezza Rice to Reagan Secretary of State George Shultz. 

Unsurprisingly given the politics of his employer, Atlas’ public statements tend to delight conservatives and alarm scientists who study public health and infectious diseases. Atlas recently tweeted that masks do not work to prevent infection (an unsupported claim, and one which Twitter wound up taking down for being misleading); previously, he claimed publicly that the threat of the coronavirus is greatly exaggerated. Atlas also claimed that summer civil rights protests were to blame for coronavirus outbreaks, as well as proximity to the U.S.-Mexico border, two more claims for which there is no evidence.

Despite being described by Trump as “one of the great experts of the world,” Atlas is reported to not have expertise in infectious disease mitigation or public health. Most recently, Atlas raised eyebrows last week for appearing on Russian state broadcaster RT, which is registered with the Justice Department as an agent of the Russian government.

Related Articles

David Spiegel, a medicine professor and associate chair of the Department of Psychiatry and Behavioral Sciences, claimed during the late October meeting (which occurred before the RT interview) that Atlas is the “latest member of the Hoover Institution to disseminate incorrect and unscientific information about the coronavirus pandemic,” according to Stanford News. He also accused Atlas of violating the American Medical Association’s Code of Ethics and claimed that he may have additionally violated Stanford’s Code of Conduct.

University President Marc Tessier-Lavigne responded by citing the college’s Statement on Academic Freedom, although the provost acknowledged the validity of engineering professor Stephen Monismith’s concern about a New York Times report that some of Trump’s senior economic advisers had

Read more

University of Chicago Medicine looking for 2,000 participants for COVID-19 vaccine trial

University of Chicago Medicine will soon begin testing another potential COVID-19 vaccine, and is looking for up to 2,000 people to enroll in the phase three clinical trial.



Medical assistant Debbie Turrise assists patients driving thru with self administered COVID-19 tests at a COVID-19 drive-thru testing site at Rush University Medical Center in Chicago, Tuesday, Oct. 20, 2020. University of Chicago Medicine will soon begin testing another potential COVID-19 vaccine, and is looking for up to 2,000 people to enroll in the phase three clinical trial.


© Antonio Perez / Chicago Tribune/Chicago Tribune/TNS
Medical assistant Debbie Turrise assists patients driving thru with self administered COVID-19 tests at a COVID-19 drive-thru testing site at Rush University Medical Center in Chicago, Tuesday, Oct. 20, 2020. University of Chicago Medicine will soon begin testing another potential COVID-19 vaccine, and is looking for up to 2,000 people to enroll in the phase three clinical trial.

The trial is designed to evaluate the safety and efficacy of a single dose of a vaccine produced by Janssen Pharmaceutical Companies of Johnson & Johnson. The trial began enrolling 60,000 adults across the world in September.

Loading...

Load Error

It’s one of a handful of potential vaccines now in advanced clinical trials in the U.S.

The international trial of the Janssen vaccine was temporarily paused in October after one participant developed an unexplained illness.

“Such pauses are not uncommon in vaccine trials, and late last week the FDA approved the resumption of the trial after an independent committee found the vaccine did not cause the illness,” University of Chicago Medicine leaders wrote in an email sent Monday to faculty, staff and students.

This is the second COVID-19 vaccine trial University of Chicago Medicine has offered. Since mid-September, the system has also been enrolling subjects in the Moderna COVE trial.

To participate in the Janssen trial and future research, people can join UChicago Medicine’s registry.

Other large hospital systems in Chicago are also participating in COVID-19 vaccine trials, including the University of Illinois at Chicago, which is part of the Moderna trial, and Northwestern Medicine, which is part of a trial of the AstraZeneca Oxford vaccine.

———

©2020 the Chicago Tribune

Visit the Chicago Tribune at www.chicagotribune.com

Distributed by Tribune Content Agency, LLC.

Continue Reading

Source Article

Read more

School of Nursing and Rehabilitation of Shandong University Inaugurated

Image 1

The School of Nursing and Rehabilitation of SDU was inaugurated
The School of Nursing and Rehabilitation of SDU was inaugurated
The School of Nursing and Rehabilitation of SDU was inaugurated

Image 2

The inauguration of the new School
The inauguration of the new School
The inauguration of the new School

SHANDONG, China, Nov. 02, 2020 (GLOBE NEWSWIRE) — On October 20th, the School of Nursing and Rehabilitation was inaugurated on the Baotuquan Campus of Shandong University.

Guo Xinli, Secretary of the CPC Shandong University Committee said that nursing and rehabilitation, a field with promising prospects and tremendous potential in China, were a key sector in China’s health service system and health industry. He hopes that by sticking to first-rate standards and striving to attain world-class quality, the School of Nursing and Rehabilitation will become a cradle for fostering talent, a platform for innovation and a center of teaching, research and development.

Shandong University is known to be one of the originating universities of China’s higher education on nursing. It is among China’s first batch of first-level doctoral programs and master programs on nursing, having cultivated a large number of leading nursing talents and won high recognition from the public.

According to Wang Kefang, dean of the School of Nursing and Rehabilitation, the School will cooperate with first-rate universities at home and abroad to consolidate its advantageous resources in nursing and rehabilitation, reshape its disciplinary layout, and cultivate its top disciplinary growth. Moreover, it will promote innovation on plural or multiple talent cultivation models, like the “nursing plus” and micro majors, and organize its faculties with full-time teachers as pillar strength supported by external teaching resources. It will encourage closer cooperation from development, teaching and research to turn out more scientific research results, and introduce a coordinated working mechanism for better university-school and industry-teaching integration.

The School of Nursing and Rehabilitation, established on the basis of faculties and researchers of the former School of Nursing, is an independent teaching and research unit directly attached to the University, but integrating resources from clinical units and strategic partners such as Qilu Hospital and the Second Hospital of Shandong University.

Two photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/904db359-3a92-4389-94c9-5b661b86fa64
https://www.globenewswire.com/NewsRoom/AttachmentNg/4a90ff33-1f80-416e-abc2-cec1cd3688be

Contact:

Xie Tingting
+86 15063349812
[email protected] 

Source Article

Read more

Barry University School of Podiatric Medicine Goes Live with MTBC’s CareCloud

CareCloud’s solutions will further modernize the school’s outpatient centers and enhance clinical operations for its post-graduate residency program

SOMERSET, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) — MTBC, Inc. (Nasdaq: MTBC) (Nasdaq: MTBCP), a leading provider of cloud-based healthcare IT solutions and services, today announced that Barry University’s School of Podiatric Medicine is live with MTBC’s CareCloud solutions, including revenue cycle management services (RCM), practice management (PM) software, electronic health records (EHR), and patient experience solutions. CareCloud’s platform will promote operational efficiency and cost-effectiveness at the University’s outpatient podiatry centers.

“At the Barry University Foot and Ankle Institute, providing state-of-the-art care and treatment for disorders of the foot and ankle, and a first-class patient experience, are our trademarks,” said Dr. Steven Becker, Clinics Administrator. “We are pleased to work with CareCloud to further enhance the patient experience with a new electronic health record platform, including an engaging, interactive patient portal and quick and easy online appointment scheduling.”

By implementing CareCloud’s full suite of RCM, EHR, and PM solutions, the University’s podiatry clinics will streamline clinical and operational workflows, enrich the overall patient experience, and identify and capture lost revenue opportunities. Each year, over 150 podiatry students participate in Barry University’s curriculum, and each one will have the opportunity to experience CareCloud’s robust clinical and operational solutions.

“More than 50 podiatrist students graduate from Barry University each year, and we are honored to provide the operational and clinical technology that supports the training of these future physicians,” said Wes Stolp, Executive Vice President of Sales, MTBC. “It is our mission to enable Barry University to maintain a growing, profitable clinic that, in turn, produces successful and well-trained Doctors of Podiatric Medicine.”

CareCloud is committed to supporting healthcare providers with cloud-based clinical, financial, and administrative software and services that enhance practice operations. Barry University is a prime example of such a partnership, not only leveraging CareCloud’s state-of-the-art tools to boost revenues but utilizing podiatric-specific features to enrich patient care.

About Barry University

Barry University is located in Miami Shores, Florida, and is a private, Catholic institution with a history of academic excellence in the Dominican tradition. Founded in 1940, the University enrolls approximately 7,500 students across undergraduate and graduate programs. The School of Podiatric Medicine was founded in 1985 with the purpose of graduating competent podiatric physicians qualified to enter post-graduate training. This is accomplished by excellence in podiatric medical education, fostering life-long learning, expressing a commitment to social justice by serving the local and global community through patient care, and encouraging research and innovation that promotes the common good.

For additional information about Barry University, visit our website at www.barry.edu. To learn more about the School of Podiatric Medicine, visit www.barry.edu/podiatry.

Follow Barry University on LinkedIn and Facebook.

About MTBC

MTBC is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, together with related business services, to healthcare providers and hospitals throughout the United States. Our Software-as-a-Service (or SaaS) platform includes

Read more

‘Aspirational’ students cause jump in university applications for Oxbridge and medicine in 2021

Students are being “aspirational” with their university choices for 2021, with applications to the most competitive courses seeing a significant jump, Ucas has said. 

According to figures released by the admissions service, a total of 44,220 UK students – up 14 per cent on last year – have applied to undergraduate courses with the early application deadline of 15 October. 

This is the deadline for those wanting to study at Oxford, Cambridge and for most medicine, dentistry and veterinary courses at other universities.

Applications up

A record 2,800 18 year-olds from disadvantaged backgrounds in the UK have applied (Photo: Steve Parsons/PA Wire)

The increase in applications has come despite grim scenes of rampant Covid-19 outbreaks at many universities and locked down student halls. 

A record 2,800 18 year-olds from disadvantaged backgrounds in the UK have applied – an increase of 19 per cent on last year. This compared to an 8 per cent increase in applicants from the most privileged backgrounds to reach 17,140. 

International applicants from outside the EU increased by 20 per cent to 17,510, but EU applicants dropped by 19 per cent to 5,220. 

‘Students aim high’

Clare Marchant, the chief executive of Ucas, said: “It’s great news to see students aim high and aspire to a future beyond the current limits of Covid with their choices for next year.” 

The main deadline for university applications is 15 January 2021. 

The figures from Ucas came as a survey found the majority of young people who applied to university this year think it would be fairer to overhaul the system so students only submit an application once they have their final grades. 

Post qualification applications

The research from the Sutton Trust social mobility found that working-class applicants were more likely to say they would have applied to a more selective university if they had known their A-level results when making decisions. 

Two in three (66 per cent) of university applicants said they favour a move to a post-qualification applications (PQA) system rather than university offers based on predicted grades. 

Sir Peter Lampl, founder and chairman of the Sutton Trust, said: “The utter chaos of this year’s university admissions exposed major flaws with the system that are due principally to our reliance on predicted grades. Two thirds of young people support PQA which allows both them and universities to make decisions based on actual grades. It’s as if applicants have real currency in their possession, rather than counterfeit currency as is now the case. 

“PQA would benefit high achieving low income students as their grades are often underpredicted. PQA would also result in admissions becoming more efficient, simpler and fairer for all students.” 

Source Article

Read more